SEC Filing | Arbutus Biopharma Corporation

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lutwyche Peter

(Last)

(First)

(Middle)

C/O ARBUTUS BIOPHARMA CORP.

SUITE 100, 8900 GLENLYON PARKWAY

(Street)

BURNABY

V5J 5J8

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/03/2015

3. Issuer Name and Ticker or Trading Symbol
Arbutus Biopharma Corp [ ABUS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Tech. Operations Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	38,758	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (Right to Buy)	12/10/2012	12/09/2022	Common Shares	5,000	5.15⁽¹⁾	D
Employee Stock Option (Right to Buy)	02/05/2014⁽²⁾	02/04/2024	Common Shares	20,000	16.4⁽¹⁾	D
Employee Stock Option (Right to Buy)	03/30/2015⁽³⁾	03/30/2025	Common Shares	65,000	17.57	D
Employee Stock Option (Right to Buy)	07/09/2015⁽³⁾	03/30/2025	Common Shares	35,000	17.57	D
Warrants	02/29/2012	03/01/2017	Common Shares	2,500	2.6⁽¹⁾	D

Explanation of Responses:

1. Expressed in Canadian dollars.

2. Date reflected above is date of grant. The option vests as follows: 1/4 on 2/5/2014; 1/4 on 2/5/2015; 1/4 on 2/5/2016; and 1/4 on 2/5/2017.

3. Date reflected above is date of grant. The option vests as follows: 1/3 on 3/30/2016; 1/3/ on 3/30/2017; and 1/3 on 3/30/2018.

Remarks:

	/s/ Peter Lutwyche	12/22/2015
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.